89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.